Latest News From Pharmachem

    March 2012

  • GSK announces submissions for two influenza vaccines

    GSK announces submissions for two influenza vaccines

    06 March, 2012

    GSK has submitted US and EU regulatory applications seeking approval of a quadrivalent influenza vaccine for the "active immunisation of adults and children from 3 years of age for the prevention of influenza disease caused by influenza virus types A and B contained in the vaccine."

    Continue Reading »

  • Pfizer's Prevnar 13® shown to be immunogenic in older children and adolescents

    Pfizer's Prevnar 13® shown to be immunogenic in older children and adolescents

    13 March, 2012

    Pfizer Inc. (NYSE:PFE) announced that data from a Phase 3 study of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years. These data, which are being presented today during the 8th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in Iguacu Falls, Brazil, will support planned regulatory submissions seeking to expand the Prevnar 13 label in the United States, the European Union, and other countries around the world.

    Continue Reading »

  • Cell discovery strengthens quest for cancer treatments

    20 March, 2012

    Fresh insights into how our cells multiply could help scientists develop drugs to treat cancer. Researchers have gained better understanding of the workings of two key proteins that control cell division. This process must be carried out accurately to keep cells healthy, and when it goes out of control, it can lead to cancer.

    Continue Reading »

  • 9th Cork Lifelong Learning Festival

    22 March, 2012

    Monday March 26 to Sunday April 1, 2012

    Continue Reading »

  • The path to personalized cancer treatment

    The path to personalized cancer treatment

    29 March, 2012

    In the largest study of its kind, researchers have profiled genetic changes in cancer with drug sensitivity in order to develop a personalised approach to cancer treatments. The study is published in Nature on Thursday 29 March 2012.

    Continue Reading »